What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Surgery
His main research concerns Internal medicine, Gastroenterology, Cirrhosis, Surgery and Hepatocellular carcinoma.
His Endocrinology research extends to Internal medicine, which is thematically connected.
His work in the fields of Hepatology overlaps with other areas such as Placebo-controlled study.
His Cirrhosis study combines topics in areas such as Liver disease and Decompensation.
His biological study spans a wide range of topics, including Multivariate analysis and Hazard ratio.
His research in Hepatocellular carcinoma intersects with topics in Cancer, Liver function, Oncology and Pathology.
His most cited work include:
- The burden of liver disease in Europe. A review of available epidemiological data. (834 citations)
- Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. (385 citations)
- Hepatocyte IKKβ/NF-κB Inhibits Tumor Promotion and Progression by Preventing Oxidative Stress-Driven STAT3 Activation (336 citations)
What are the main themes of his work throughout his whole career to date?
Markus Peck-Radosavljevic spends much of his time researching Internal medicine, Gastroenterology, Hepatocellular carcinoma, Cirrhosis and Portal hypertension.
His Internal medicine research incorporates elements of Surgery and Oncology.
Markus Peck-Radosavljevic has included themes like Hepatitis C, Immunology, Ribavirin and Liver transplantation in his Gastroenterology study.
His research integrates issues of Liver function and Carcinoma, Pathology in his study of Hepatocellular carcinoma.
His Cirrhosis research is multidisciplinary, incorporating perspectives in Endocrinology and Radiology.
He does research in Portal hypertension, focusing on Transjugular intrahepatic portosystemic shunt specifically.
He most often published in these fields:
- Internal medicine (63.09%)
- Gastroenterology (39.19%)
- Hepatocellular carcinoma (23.55%)
What were the highlights of his more recent work (between 2016-2021)?
- Internal medicine (63.09%)
- Gastroenterology (39.19%)
- Hepatocellular carcinoma (23.55%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Internal medicine, Gastroenterology, Hepatocellular carcinoma, Portal hypertension and Cirrhosis.
As part of his studies on Internal medicine, he often connects relevant areas like Oncology.
His study in Gastroenterology is interdisciplinary in nature, drawing from both Ribavirin, Sofosbuvir, Liver transplantation and Hepatitis C.
His Hepatocellular carcinoma study combines topics from a wide range of disciplines, such as Cancer, Liver function, Carcinoma and Phases of clinical research.
His work deals with themes such as Endocrinology, Virologic response, Transient elastography, Radiology and Hepatic decompensation, which intersect with Portal hypertension.
The Cirrhosis study combines topics in areas such as Decompensation, Univariate analysis and Ascites.
Between 2016 and 2021, his most popular works were:
- Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study (160 citations)
- [Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection]. (142 citations)
- Treatment with ledipasvir-sofosbuvir for 12 or 24 weeks in kidney transplant recipients with chronic hepatitis C virus genotype 1 or 4 infection: A randomized trial (129 citations)
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
